HLA Typing for Transplant Market Overview
The HLA typing for transplant market is estimated to reach $1,136 million by 2026 and is poised to grow at a CAGR of 7.4% over the forecast period of 2021-2026. HLA or Human Leukocyte antigen is a common protein antigen inherited from the parental generation. A person would receive six-vital HLA, three from both the parents. The antigens have been coded as A2, A30, B8, B70, DR3, and DR8. Antigens are the markers present in one’s body, which helps one distinguish from the other human being. The typing/matching test is prevalent to avoid complications such as graft versus host disease, which is caused when the body tries to eliminate the graft and the immune response or WBCs are set to counter it as one of the viruses or bacteria. Moreover, major histocompatibility complex owing to GVHD, doctors are preferring cord blood transplants as the chances reduce by up to 50%. Moreover, transplant diagnostics have to be run in order to find out any form of virus or immuno-acquired diseases, which have the potential to prove fatal to the recipient.
The increasing number of organ transplants and the associated technology along with the rising geriatric population are some of the factors driving the HLA typing for the transplant industry forward in the projected period of 2021-2026.
The report: “HLA Typing for Transplant Market Forecast (2021-2026)”, by Industry ARC covers an in-depth analysis of the following segments of the HLA typing for the transplant market.
- Geographically, North America’s HLA typing for transplant held a dominant market share in the year 2020. It is owing to the advent and adoption of technologically advanced tools and products which have eased the entire process. However, Asia-Pacific offers lucrative opportunities to the marketers owing to the rising geriatric population and increased expenditure for realizing better healthcare infrastructure.
- A rising geriatric population along with their tendency of having transplants has been recognized as a ready driver for the market. However, the high costs associated with and chances of developing GVHD has acted as a grave market challenge.
- A detailed analysis of the strengths, weaknesses, opportunities, and threats will be provided in the HLA typing for transplant market report.
HLA Typing for Transplant Market Share, By Technology, 2020(%)
HLA Typing for Transplant Market Segmentation Analysis- By Technology
The HLA typing for the transplant market based on technology can be further segmented into molecular assay and non-molecular assay technologies. The molecular assay technology dominated the market in the year 2020. It is owing to the high efficacy and low error rate of the following technology. PCR tests readily help recognize the pathogens or antigens present in the sample, and due to their various sizes (desk and standing), laboratories and various end-users have preferred them over the others.
Moreover, molecular assay technology is estimated to be the fastest-growing, with a CAGR of 7.9% over the forecast period of 2021-2026. It is owing to the recent advancements in the industry after the pandemic struck, and the heavy usage of PCR tests to detect the Sars Antigen forced the innovators to look for more sustainable machines which can be a hybrid module and would allow them to move forward after the pandemic ends. Additionally, PCR technology can deliver qualitative and quantitative results within a day or hours after the sample collection.
HLA Typing for Transplant Market Segmentation Analysis- By End Users
The HLA typing for the transplant market based on end-users can be further segmented into Independent Reference Laboratories, Hospital and Transplant Center, and Research Laboratories & Academic Institutes. The hospital and transplant segment held a dominant market share in the year 2020. It is owing to the multiple specialty hospitals catering to varied demands and having established in-house testing facilities to smooth the entire process. For example, Medical City Dallas has grown out to be the fastest-growing transplant center and has grown by about 310% in three years.
Further, the hospital and transplant center is estimated to be the fastest-growing, with a CAGR of 8.1% over the forecast period of 2021-2026. It is owing to the rising number of chronic kidney diseases across the world owing to cardiovascular diseases such as diabetes. As per CDC, 1 in 3 people is at risk of developing such diseases, and there are more than 100,000 people on the waiting list for such transplants. The following would augment the growth of the HLA typing for the transplant market in the projected period.
HLA Typing for Transplant Market Segmentation Analysis- By Geography
The HLA typing for the transplant market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America’s HLA typing for transplant market held a dominant market share of 37% over the others. It is owing to the ready deployment of the latest technologies which brings down the fatalities. Moreover, the government spending on healthcare in the region is by far the highest as compared to other geographies, which has resulted in increased R&D activities. As per the CDC, the US spends $11,582 per person, and the share of healthcare spending is close to 17.7% of the entire GDP.
However, Asia-Pacific offers lucrative opportunities to marketers. It is owing to the rising concerns of government and private bodies to improve medical conditions. To fulfill those commitments, the region has seen an increase in healthcare spending over the last decade. Countries such as Korea and Japan have been the pioneer of healthcare technology and the introduction of IoT in various deployments. Additionally, India saw a 137% rise in healthcare spending from 2019. Such developments across the region will help in the growth of the HLA typing for the Transplant market in the projected period of 2021-2026.
HLA Typing for Transplant Market Drivers
The advent of the latest technology has readily supplanted the HLA typing for the transplant market.
The use of UCB or Umbilical cord blood in place of bone marrow has helped the market. It is owing to the former’s ability to provide better results than the latter. Additionally, as per various research, the use of cord blood can reduce the chances of developing GVHD or graft versus host disease to less than 10%, which for bone marrow stands at 60%. Additionally, it is found that cord blood transplants have a lower potency of developing tumors over a lifetime, and the chance of viral contamination is low. Moreover, the following allows for high cell proliferation capacity. The use of HLA typing or matching can further progress the use of the UCB in un-related or racial or ethical minorities whose genetic variations are not yet registered in the feed. The following advent has helped in the growth of the market.
The rising number of geriatric patients will assist the demand for HLA typing.
As per the US Healthcare and Human Services, most of the patients needing a transplant have been in the age bracket above 50 years or were above 64 years. It is owing to the natural tendency of the organs to stop functioning healthy after a sedentary lifestyle and other cardiovascular ailments like diabetes. Additionally, the US CDC projects a boom in the geriatric population in the fore coming times and period. As per them, by 2034, the young adults and those above 65+ will break even and there would be a ready demand for better and advanced technology to assist them during transplants and other ailments.
HLA Typing for Transplant Market Challenges
The cases of severe GVHD have dampened the confidence in HLA typing and have acted as a grave market challenge.
The incidence of severe or moderate GVHD has been rising in the 7MM. Moreover, epidemiologists have associated various factors which have resulted in the prevalence of the disease by up to 70%. Donor recipient parity or low gene antigen matching and graft source have been attributed as the “primary reason.” Additionally, GVHD arises when the patient's (recipient’s) body attacks the graft given by the donor, as it identifies it as the potential threat from a foreign substance; cases of fatality have been recorded in occurrences of allogeneic stem cell transplantation. However, the researchers are trying to find the early stages at which the disease’s severity can be dampened.
HLA Typing for Transplant Market Competitive Landscape
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the HLA typing for transplant market. The top 10- HLA typing for transplant market companies include:
- Thermo Fisher Scientific, Inc.
- QIAGEN N.V, I
- CareDx, Inc.
- Immucor, Inc.
- Bio-Rad Laboratories, Inc.
- F. Hoffman-La Roche Ltd.
- Hologic, Inc.
HLA Typing for Transplant Market Developments
- In November 2019, Thermo Fischer Scientific introduced their “Ion Torrent Genexus System.” The system is a fully integrated next-gen sequencing platform that would allow for the automated specimen to reporting workflow in a single day. Further, the company’s aim is to enable the local hospitals to adapt to the NGS testing feature.
- In March 2019, QuantuMDx had developed a novel, low-cost sample which allows the users/hospitals to use the molecular diagnostics technology at both low and high levels. Additionally, the device is capable of handling qPCR and end-PCR with a help of micro-array. Additionally, the test guarantees result within 30 minutes which will help in screening more individuals.